BioXcel Therapeutics, Inc. BTAI 深 沪
交易中 06-24 11:41:07 美东时间
1.35
+0.090
+7.14%
华盛通- 最 高1.3579
- 今 开1.27
- 成交量 23.26万股
- 最 低 1.27
- 昨 收 1.26
- 总市值 4168.48万
- 52周最高 8.08
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 1.01
- 委 比 30.43%
- 总股本 3087.76万
- 历史最高 1144.00
- 量 比 1.14
- 振 幅 6.98%
- 历史最低 1.01
- 每 手 1
- 风险率 1.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioXcel Presents New Data From Phase 3 SERENITY At-Home Trial Evaluating BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia At 2026 ASCP Annual Meeting
BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the presentation of new positive data
05-28 19:04
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Bioxcel Issues Warrants in Private Equity Financing Deal
Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. On March 27, 202...
04-18 05:59
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
The FDA Accepts Its Bioxcel Therapeutics' Supplemental New Drug Application For Igalmi For At-home Use In The Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia, PDUFA Date Of November 14
Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting
04-01 19:04
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
BioXcel Therapeutics Q4 EPS $(0.58) Beats $(0.69) Estimate, Sales $256.000K Beat $250.000K Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.69) by 16.31 percent. This is a 83.75 percent increase over losses of $(3.57) per share
03-27 19:04
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $17
Rodman & Renshaw analyst Michael King initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $17.
03-17 20:06
BioXcel Therapeutics Announces Registered Direct Equity Financing
Bioxcel Therapeutics ( ($BTAI) ) just unveiled an update. On March 10, 2026, Bi...
03-12 09:09
